BioCryst Pharmaceuticals (NASDAQ:BCRX) Raised to “Strong-Buy” at Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research firms also recently weighed in on BCRX. JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th. Cantor Fitzgerald increased their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Weiss Ratings downgraded BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Wedbush decreased their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada lowered BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $13.00 to $11.00 in a research report on Thursday, September 10th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $19.44.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.65 on Friday. The company has a fifty day moving average of $8.79 and a 200-day moving average of $9.09. The firm has a market capitalization of $1.95 billion, a P/E ratio of -5.10 and a beta of 0.55. BioCryst Pharmaceuticals has a twelve month low of $6.23 and a twelve month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.15 EPS. On average, analysts anticipate that BioCryst Pharmaceuticals will post -2.28 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Nykredit A S acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $27,000. IFP Advisors Inc lifted its stake in shares of BioCryst Pharmaceuticals by 2,515.3% in the second quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 3,119 shares in the last quarter. Allworth Financial LP acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at about $52,000. Hilltop Holdings Inc. acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $98,000. Finally, Sterling Capital Management LLC grew its holdings in shares of BioCryst Pharmaceuticals by 1,373.8% during the third quarter. Sterling Capital Management LLC now owns 12,056 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 11,238 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.